AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC’s 36^th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021.

Presentation Details

Abstract Title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer
Abstract Number: 429
Presenter: Nehal J. Lakhani, MD, PhD, START Midwest
Date: November 12^th - 14^th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint (ARC) Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas
Abstract Number: 494
Presenter: Melissa Johnson, MD, Sarah Cannon Research Institute
Date: November 12^th - 14^th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics That Stimulate Target Cells to Migrate from the Peripheral Blood
Abstract Number: 3
Presenter: Louis Gonzalez, PhD, Shattuck’s Director of Translational Research
Date: November 12^th - 14^th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-tumor Immunity in the Setting of PD-1 and TIGIT Checkpoint Blockade  
Abstract Number: 585
Presenter: George Fromm, PhD, Shattuck’s Vice President of Research & Development
Date: November 12^th - 14^th
Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Further information about the Society for Immunotherapy of Cancer Meeting can be found at:
https://www.sitcancer.org/2021/home

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
[email protected]

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
[email protected]